“According to Chinese Medicine News, Vertex Pharmaceuticals, Inc. today reported that drug VX-509’s study for the treatment of rheumatoid arthritis (RA) on Phase Ⅱmet its primary goal.

Involving 204 cases have been reported in patients with mid-term test results showed that after 12 weeks of treatment, compared with placebo, VX-509's four highest test dose of 2 groups of patients with signs, symptoms and disease activity was significantly reduced.

Based on this, the company plans to conduct a six-month mid-term study to evaluate VX-509.”